Fresenius offers international diversification, stable healthcare exposure, and upside from a strategic pivot. Find out why ...

Renalyx Health Systems launches AI-enabled dialysis machine RxT21 with real-time monitoring at ₹6.7 lakh, plans to scale ...

The Global Home Healthcare Market share is projected to be valued at USD 420.79 billion in 2024 and reach USD 666.91 billion ...

Fresenius Medical Care (FME) has commenced the US commercialisation of its high-volume haemodiafiltration (HVHDF) kidney ...

Veteran broker Cres Gardner, vice president of Beau Box Commercial Real Estate, predicts steady occupancy, higher rental ...

Fresenius Kabi Canada, part of Fresenius group, announced the recent launch of Iodixanol Injection 270 and 320 for both the ...

PL BioScience GmbH, a German life science company, has appointed Oliver Dick, PhD, as Chief Technology Officer.

RxT 21 with a starting price of ₹6.70 lakh, with an aim to reduce the total cost of ownership by 40% compared to imported alternatives.

Fresenius (FMS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

BAD HOMBURG, Germany, June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second ...